Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study

Cancer ◽

10.1002/cncr.34014 ◽

2021 ◽

Author(s):

Howard M. Katzenstein ◽

Marcio H. Malogolowkin ◽

Mark D. Krailo ◽

Jin Piao ◽

Alexander J. Towbin ◽

...

Keyword(s):

Oncology Group ◽

Oncology Group Study

Download Full-text

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70331-2 ◽

2007 ◽

Vol 2007 ◽

pp. 82-83

Author(s):

J.T. Thigpen

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Whole Abdominal Radiotherapy in the Adjuvant Treatment of Patients With Stage III and IV Endometrial Cancer: A Gynecologic Oncology Group Study

Yearbook of Obstetrics Gynecology and Women s Health ◽

10.1016/s1090-798x(08)70597-6 ◽

2006 ◽

Vol 2006 ◽

pp. 449-452

Author(s):

S.D. Yamada

Keyword(s):

Endometrial Cancer ◽

Adjuvant Treatment ◽

Gynecologic Oncology ◽

Stage Iii ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Abdominal Radiotherapy

Download Full-text

Faculty Opinions recommendation of Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1099117.555349 ◽

2008 ◽

Author(s):

Neyssa Marina

Keyword(s):

Acute Lymphoblastic Leukemia ◽

Lymphoblastic Leukemia ◽

Oncology Group ◽

Oncology Group Study ◽

Download Full-text

Faculty Opinions recommendation of Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1161714.623302 ◽

2009 ◽

Author(s):

William Tap

Keyword(s):

Ewing Sarcoma ◽

Oncology Group ◽

Standard Chemotherapy ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717948619.793453725 ◽

2012 ◽

Author(s):

David Kushner ◽

Shitanshu Uppal

Keyword(s):

Cervical Cancer ◽

Clinical Oncology ◽

Phase Ii ◽

Phase Ii Trial ◽

Uterine Cervical Cancer ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954686.793461217 ◽

2012 ◽

Author(s):

Nicolas Mounier

Keyword(s):

Mantle Cell Lymphoma ◽

Phase Ii ◽

Phase Ii Study ◽

Cell Lymphoma ◽

Eastern Cooperative Oncology Group ◽

Oncology Group ◽

Ibritumomab Tiuxetan ◽

Oncology Group Study ◽

Mantle Cell ◽

Download Full-text

Faculty of 1000 evaluation for Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717962364.793467463 ◽

2012 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Ovarian Cancer ◽

Clinical Oncology ◽

Phase Ii ◽

Intraperitoneal Chemotherapy ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Debulking Surgery ◽

Oncology Group Study ◽

Interval Debulking Surgery

Download Full-text

Faculty Opinions recommendation of Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969752.793471344 ◽

2013 ◽

Author(s):

David Kushner ◽

Ryan Spencer

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study

Download Full-text

Faculty Opinions recommendation of A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.722006345.793527263 ◽

2017 ◽

Author(s):

Paola Gehrig

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Download Full-text

Faculty Opinions recommendation of Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726377012.793527326 ◽

2017 ◽

Author(s):

Katherine Fuh

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text